Triple

T21057656
Position Surface form Disambiguated ID Type / Status
Subject ocrelizumab E518760 entity
Predicate bindingTargetLocation P50543 FINISHED
Object B lymphocytes NE NERFINISHED

How this triple was built (3 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: B lymphocytes | Statement: [ocrelizumab, bindingTargetLocation, B lymphocytes]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07
Target entity: B lymphocytes
Context triple: [ocrelizumab, bindingTargetLocation, B lymphocytes]
  • A. B lymphocytes chosen
    B lymphocytes are a type of white blood cell central to the adaptive immune system, responsible for producing antibodies and mediating humoral immunity.
  • B. T lymphocytes
    T lymphocytes are white blood cells central to the adaptive immune system, responsible for recognizing specific antigens and orchestrating targeted immune responses.
  • C. CD4+ T cells
    CD4+ T cells are a subset of immune cells that coordinate and regulate the body’s adaptive immune response, playing a central role in defending against infections.
  • D. CD8+ T cells
    CD8+ T cells are cytotoxic lymphocytes of the adaptive immune system that identify and kill infected or malignant cells by recognizing antigenic peptides presented on MHC class I molecules.
  • E. CD19
    CD19 is a B-cell surface protein widely used as a key immunotherapy target in treatments for B-cell malignancies such as certain leukemias and lymphomas.
  • F. None of above.
  • G. Unsure - the case is ambiguous/there is not enough information to decide.
PD Predicate disambiguation gpt-5-mini-2025-08-07
Target predicate: bindingTargetLocation
Context triple: [ocrelizumab, bindingTargetLocation, B lymphocytes]
  • A. locationOfBinding chosen
    Indicates the specific place or site where a binding interaction between entities occurs.
  • B. targetLocation
    Indicates the specific place or destination toward which an action, movement, or effect is directed.
  • C. bindingFor
    Indicates that one entity serves as the binding, constraint, or linkage mechanism that determines how another entity is associated, applied, or made effective.
  • D. bindingAsTo
    Indicates that one entity is legally or contractually binding upon another entity with respect to certain terms, obligations, or conditions.
  • E. bindingOption
    Indicates a relationship where one entity specifies or constrains how another entity is bound, attached, or associated within a given context or configuration.
  • F. None of above.

Provenance (3 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69e0b5053ac48190921529544959e906 completed April 16, 2026, 10:08 a.m.
NER Named-entity recognition batch_69e6fd81434c8190aedfddf937f82322 completed April 21, 2026, 4:30 a.m.
PD Predicate disambiguation batch_69e5dbf9d71881908cd85dfc37db93ca completed April 20, 2026, 7:55 a.m.
Created at: April 16, 2026, 2:37 p.m.